Targeting pituitary adenomas with folate-conjugated multiple drug decorated liposomal formulations for improved antiproliferative anticancer efficacy

References

• Dai C, Liu X, Ma W, et al. The treatment of refractory pituitary adenomas. Front Endocrinol (Lausanne)). 2019;10:334.
   Google Scholar
• Lee M, Pellegata NS. Folate receptor-mediated drug targeting: a possible strategy for nonfunctioning pituitary adenomas? Endocrinology. 2013;154(4):1387–1389. Epub 2013/03/26.
   Google Scholar
• Wang H, Chen K, Yang Z, et al. Diagnosis of invasive nonfunctional pituitary adenomas by serum extracellular vesicles. Anal Chem. 2019;91(15):9580–9589.
   Google Scholar
• Dai C, Feng M, Liu X, et al. Refractory pituitary adenoma: a novel classification for pituitary tumors. Oncotarget. 2016;7(50):83657–83668.
   Google Scholar
• Liu X, Ma S, Dai C, et al. Antiproliferative, antiinvasive, and proapoptotic activity of folate receptor α-targeted liposomal doxorubicin in nonfunctional pituitary adenoma cells. Endocrinology. 2013;154(4):1414–1423.
   Google Scholar
• Chatzellis E, Alexandraki KI, Androulakis II, et al. Aggressive pituitary tumors. Neuroendocrinology. 2015;101(2):87–104. Epub 2015/01/13.
   Google Scholar
• Colao A, Di Somma C, Pivonello R, et al. Medical therapy for clinically non-functioning pituitary adenomas. Endocr Relat Cancer. 2008;15(4):905–915.
   Google Scholar
• Greenman Y. Dopaminergic treatment of nonfunctioning pituitary adenomas. Nat Clin Pract Endocrinol Metab. 2007;3(8):554–555.
   Google Scholar
• Jin S-E, Jin H-E, Hong S-S. Targeted delivery system of nanobiomaterials in anticancer therapy: from cells to clinics. Biomed Res Int. 2014;2014:814208.
   Google Scholar
• Mirnezami SMS, Heydarinasab A, Akbarzadeh A, et al. Investigation of characterization and cytotoxic effect of PEGylated nanoliposomal containing melphalan on ovarian cancer: an in vitro study. J Exp Nanosci. 2021;16(1):102–116.
   Google Scholar
• Shi J, Votruba AR, Farokhzad OC, et al. Nanotechnology in drug delivery and tissue engineering: from discovery to applications. Nano Lett. 2010;10(9):3223–3230.
   Google Scholar
• Zhang L, Gu F, Chan J, et al. Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther. 2008;83(5):761–769.
   Google Scholar
• Lammers T, Hennink W, Storm G. Tumour-targeted nanomedicines: principles and practice. Br J Cancer. 2008;99(3):392–397.
   Google Scholar
• Lammers T, Kiessling F, Hennink WE, et al. Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. J Control Release. 2012;161(2):175–187.
   Google Scholar
• Paulos CM, Reddy JA, Leamon CP, et al. Ligand binding and kinetics of folate receptor recycling in vivo: impact on receptor-mediated drug delivery. Mol Pharmacol. 2004;66(6):1406–1414.
   Google Scholar
• Bhattacharya S. Methotrexate-loaded polymeric lipid hybrid nanoparticles (PLHNPs): a reliable drug delivery system for the treatment of glioblastoma. J Exp Nanosci. 2021;16(1):345–368.
   Google Scholar
• Zhao X, Li H, Lee RJ. Targeted drug delivery via folate receptors. Expert Opin Drug Deliv. 2008;5(3):309–319.
   Google Scholar
• Liu Q, Lee RJ. Folate receptor targeted liposomes. DDRO. 2005;2(7):547–552.
   Google Scholar
• Low PS, Kularatne SA. Folate-targeted therapeutic and imaging agents for cancer. Curr Opin Chem Biol. 2009;13(3):256–262.
   Google Scholar
• Didion C, Henne WA. Bibliometric analysis of folate receptor research: a comprehensive bibliometric analysis of the entire field of folate receptor research. 2020.
   Google Scholar
• Galt JR, Halkar RK, Evans C-O, et al. In vivo assay of folate receptors in nonfunctional pituitary adenomas with 99mTc-folate SPECT/CT. J Nucl Med. 2010;51(11):1716–1723.
   Google Scholar
• Evans C-O, Reddy P, Brat DJ, et al. Differential expression of folate receptor in pituitary adenomas. Cancer Res. 2003;63(14):4218–4224.
   Google Scholar
• Guo Y, Sun Z. Investigating folate-conjugated combinatorial drug loaded ZnO nanoparticles for improved efficacy on nasopharyngeal carcinoma cell lines. J Exp Nanosci. 2020;15(1):390–405.
   Google Scholar
• Moreno CS, Evans C-O, Zhan X, et al. Novel molecular signaling and classification of human clinically nonfunctional pituitary adenomas identified by gene expression profiling and proteomic analyses. Cancer Res. 2005;65(22):10214–10222.
   Google Scholar
• Evans CO, Yao C, LaBorde D, et al. Folate receptor expression in pituitary adenomas cellular and molecular analysis. Vitam Horm. 2008;79:235–266.
   Google Scholar
• Yao C, Evans C-O, Stevens VL, et al. Folate receptor alpha regulates cell proliferation in mouse gonadotroph alphaT3-1 cells. Exp Cell Res. 2009;315(18):3125–3132.
   Google Scholar
• Verma A, Jain A, Tiwari A, et al. Folate conjugated double liposomes bearing prednisolone and methotrexate for targeting rheumatoid arthritis. Pharm Res. 2019;36(8):123.
   Google Scholar
• Jain A, Jain SK. Application potential of engineered liposomes in tumor targeting. Multifunctional Systems for Combined Delivery, Biosensing and Diagnostics: Elsevier; 2017. p. 171–191.
   Google Scholar
• Jain A, Gulbake A, Jain A, et al. Dual drug delivery using ‘smart’ liposomes for triggered release of anticancer agents. J Nanopart Res. 2013;15(7):1772.
   Google Scholar
• Jain A, Jain SK. Multipronged, strategic delivery of paclitaxel-topotecan using engineered liposomes to ovarian cancer. Drug Dev Ind Pharm. 2016;42(1):136–149.
   Google Scholar
• Jain A, Jain S. Advances in tumor targeted liposomes. Curr Mol Med. 2018;18:44–57.
   Google Scholar
• Ogue S, Takahashi Y, Onishi H, et al. Preparation of double liposomes and their efficiency as an oral vaccine carrier. Biol Pharm Bull. 2006;29(6):1223–1228.
   Google Scholar
• Mokale VJ, Patil HI, Patil AP, et al. Formulation and optimisation of famotidine proniosomes: anin vitroandex vivostudy. J Exp Nanosci. 2016;11(2):97–110.
   Google Scholar
• Jain A, Jain SK. In vitro release kinetics model fitting of liposomes: an insight. Chem Phys Lipids. 2016;201:28–40. Epub 2016/12/17.
   Google Scholar
• Even-Zohar N, Greenman Y. Management of NFAs: medical treatment. Pituitary. 2018;21(2):168–175.
   Google Scholar
• Greenman Y, Cooper O, Yaish I, et al. Treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists. Eur J Endocrinol. 2016;175(1):63–72.
   Google Scholar
• Greenman Y, Tordjman K, Osher E, et al. Postoperative treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists decreases tumour remnant growth. Clin Endocrinol. 2005;63(1):39–44.
   Google Scholar
• Raverot G, Castinetti F, Jouanneau E, et al. Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment. Clin Endocrinol (Oxf)). 2012;76(6):769–775.
   Google Scholar
• Lee RJ, Low PS. Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. Biochim Biophys Acta Biomembr. 1995;1233(2):134–144.
   Google Scholar
• Yamabe K, Kato Y, Onishi H, et al. In vitro characteristics of liposomes and double liposomes prepared using a novel glass beads method. J Control Release. 2003;90(1):71–79.
   Google Scholar
• Sartori T, Murakami FS, Cruz AP, et al. Development and validation of a fast RP-HPLC method for determination of methotrexate entrapment efficiency in polymeric nanocapsules. J Chromatogr Sci. 2008;46(6):505–509.
   Google Scholar
• Dangi R, Hurkat P, Jain A, et al. Targeting liver cancer via ASGP receptor using 5-FU-loaded surface-modified PLGA nanoparticles. J Microencapsul. 2014;31(5):479–487.
   Google Scholar
• Jain D, Bajaj A, Athawale R, et al. Surface-coated PLA nanoparticles loaded with temozolomide for improved brain deposition and potential treatment of gliomas: development, characterization and in vivo studies. Drug Delivery. 2016;23(3):989–1006.
   Google Scholar
• Chu L, Wang A, Ni L, et al. Nose-to-brain delivery of temozolomide-loaded PLGA nanoparticles functionalized with anti-EPHA3 for glioblastoma targeting. Drug Delivery. 2018;25(1):1634–1641.
   Google Scholar
• Evans C-O, Young AN, Brown MR, et al. Novel patterns of gene expression in pituitary adenomas identified by complementary deoxyribonucleic acid microarrays and quantitative reverse transcription-polymerase chain reaction. J Clin Endocrinol Metab. 2001;86(7):3097–3107.
   Google Scholar
• Banerjee S, Sen K, Pal TK, et al. Poly(styrene-co-maleic acid)-based pH-sensitive liposomes mediate cytosolic delivery of drugs for enhanced cancer chemotherapy. Int J Pharm. 2012;436(1-2):786–797. Epub 2012/08/14.
   Google Scholar
• Mastrobattista E, Storm G, Van Bloois L, et al. Cellular uptake of liposomes targeted to intercellular adhesion molecule-1 (ICAM-1) on bronchial epithelial cells. Biochim Biophys Acta Biomembr. 1999;1419(2):353–363.
   Google Scholar